1. GPCR/G Protein
  2. Endothelin Receptor
  3. ZD-1611

ZD-1611 

Cat. No.: HY-19274
Handling Instructions

ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.

For research use only. We do not sell to patients.

ZD-1611 Chemical Structure

ZD-1611 Chemical Structure

CAS No. : 186497-38-1

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke.

In Vitro

ZD1611 competitively inhibits 125I-labeled ET-1 binding at human cloned ETA and ETB receptors with pIC50 values of 8.6 and 5.6, respectively, showing 1000-fold selectivity for the ETA receptor[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ZD1611 (0.3 mg/kg, p.o.) has a duration of action of more than 7 h in rats. In the dog, ZD1611 is active for at least 6 h at dose of 0.6 mg/kg p.o[1]. ZD1611 (0.15 mg/kg/day) in combination with candesartan decreases the brain damage and improves the neurological scores in rats. However, ZD1611 or candesartan alone does not significantly decrease the brain damage or improve neurological scores[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

456.51

Formula

C22H24N4O5S

CAS No.
SMILES

O=C(O)C(C)(C)CC1=CC=C(C2=NC=CC=C2S(=O)(NC3=NC=C(C)N=C3OC)=O)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
Animal Administration
[1]

The precursor of ET-1, big ET-1, is used for in vivo analysis of the effects of ZD1611. Exogenously administered big ET-1 is converted to the biologically active peptide ET-1 in vivo via a phosphoramidon-sensitive ET-converting enzyme. In the present study, the use of big ET-1 in vivo is preferred because this compound fails to elicit the initial depressor response associated with i.v. administered ET-1 and yields a greater maximum response than that to ET-1 itself. A partial cumulative dose-response curve to i.v. big ET-1 starting at 0.3 nmol/kg) is constructed until pressor responses >30 mm Hg are achieved. After a 55-min recovery period, ZD1611 (0.03-0.3 mg/kg) or vehicle is administered, and the big ET-1-response curve is repeated 5 min later. The activity of ZD1611 is calculated as a ratio of the dose of big ET-1 required to give a 30-mm Hg rise in MAP in the absence and then the presence of the compound.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
ZD-1611
Cat. No.:
HY-19274
Quantity:
MCE Japan Authorized Agent: